Company: SXTPW
Filing Date: 2025-02-14
Form Type: S-1
Source: 0001213900-25-014334
Chunk: 289

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-02-14
Form: S-1
Chunk 289
---
 |   |

During the years ended December 31, 2023 and 2022, the Company capitalized website development or related costs of $ 52,178and $ 27,070, respectively, in connection with the upgrade and enhancement of functionality of the corporate website at www. 60degreespharma.com. Amortization expense for the years ended December 31, 2023, and 2022 was in the amount of $ 29,157and $ 5,118, respectively.

The following table summarizes the estimated future amortization expense for our patents and website development costs as of December 31, 2023:

| Period     |     | Patents |        |     | Website     
 Development 
 Costs       |        |
|:-----------|:----|:--------|-------:|:----|:------------|-------:|
| 2024       |     | $       |  6,612 |     | $           | 26,416 |
| 2025       |     |         |  6,612 |     |             | 23,303 |
| 2026       |     |         |  6,612 |     |             |  3,974 |
| 2027       |     |         |  6,612 |     |             |      - |
| 2028       |     |         |  6,612 |     |             |      - |
| Thereafter |     |         | 41,817 |     |             |      - |
| Total      |     | $       | 74,877 |     | $           | 53,693 |

The Company additionally has $ 93,545in capitalized patent expenses that will become amortizable as the patents they are associated with are awarded.

6. STOCKHOLDERS’ EQUITY On June 1, 2022, 60P LLC entered into the Agreement and Plan of Merger with 60 Degrees Pharmaceuticals, Inc., pursuant to which 60P LLC merged into 60 Degrees Pharmaceuticals, Inc. (the “Merger”). The value of each outstanding member’s membership interest in 60P LLC was correspondingly converted into common stock of 60 Degrees Pharmaceuticals, Inc., par value $ 0.0001per share, with a cost basis equal to $ 5per share. Pursuant to the Certificate of Incorporation of 60 Degrees Pharmaceuticals, Inc., the Company’s authorized shares consist of (a)